Par Pharmaceutical: High-Quality, Cost-Effective Generic Products
Par Pharmaceutical, headquartered in Chestnut Ridge, New York, develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical and branded injectable products that help improve patient quality of life. Par, among the top leaders in the U.S. generics industry, possesses a portfolio that includes sterile injectables, alternative dosage forms and many other differentiated products. Par is advancing a robust research and development (R&D) pipeline of potential products. Par is an operating company of Endo International plc, a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients through excellence in development, manufacturing and commercialization.
Par Pharmaceutical, headquartered in Chestnut Ridge, New York, develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical and branded injectable products that help improve patient quality of life. Par, among the top leaders in the U.S. generics industry, possesses a portfolio that includes sterile injectables, alternative dosage forms and many other differentiated products. Par is advancing a robust research and development (R&D) pipeline of potential products. Par is an operating company of Endo International plc, a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients through excellence in development, manufacturing and commercialization.
Location: United States, New York, Village of Chestnut Ridge
Employees: 1001-5000
Founded date: 1978
Investors 1
Mentions in press and media 7
| Date | Title | Description |
| 12.03.2024 | Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution | COMPANY ANNOUNCEMENT When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company. Read Announcement View Product... |
| 17.07.2012 | Par Pharmaceuticals’ generic appeal attracts $1.9 billion private equity offer | There has been quite a bit of crossover between generic and branded pharmaceutical companies with the likes of Watson and Teva keen to have the profitability that accompanies a successful branded drug with patent exclusivity lasting years i... |
| 25.11.2011 | Pozen inks $75M U.S. royalty deal for Treximet with Canadian pension fund | For the first nine months of 2011, revenues from royalties on Treximet were of $12.2 million, according to the company’s third quarter earnings report, making it the best money earner in its drug arsenal. Despite the end of regulatory exclu... |
| 22.03.2011 | N.C. pharma Pozen files court challenge to block generic competitor | Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| - | N.C. pharma Pozen files court challenge to block generic competitor | Looming patent expiration on the migraine drug Treximet has led pharmaceutical company Pozen to take further legal action to fend off generic competition. Chapel Hill, North Carolina-based Pozen (NASDAQ:POZN) said Tuesday it has filed a pre... |
| - | Par Pharmaceuticals’ generic appeal attracts $1.9 billion private equity offer | Generics producer Par Pharmaceuticals (NYSE: PRX) has been snapped up by a global private equity firm TPG in a deal that values the company at $1.9 billion, the tenth largest deal for the year to date, according to data from Dealogic. Par m... |
| - | Pozen inks $75M U.S. royalty deal for Treximet with Canadian pension fund | Pozen (NASDAQ:POZN) has sold the U.S. royalty rights for migraine drug Treximet to Canada’s national pension fund, CPPIB Credit Investments in a $75 million deal. The terms of the deal give the Chapel Hill, North Carolina pharmaceutical com... |